Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.64 |
| ▸ | PDE4A | P27815 | 12/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6031114 | 0.99 | PDE4D (0.63) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6030602 | 0.88 | PDE4A (0.75) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6027861 | 0.88 | PDE4A (0.75) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| Hydrochloric Acid SCHEMBL6028987 | 0.87 | PDE4A (0.73) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6029275 | 0.84 | PDE4B (0.78) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6031145 | 0.84 | PDE4A (0.68) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6030873 | 0.83 | PDE4A (0.65) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6030683 | 0.83 | PDE4B (0.71) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6031161 | 0.83 | PDE4B (0.73) | PDE4DPDE4APDE4BPDE4CPDE3B | |
| SCHEMBL6030198 | 0.82 | PDE4A (0.61) | PDE4DPDE4APDE4BPDE4CPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022696-B2 | Piperazino-derivatives and their use as PDE4 inhibitor | ALTANA PHARMA AG (DE) | 2006-04-04 | — | — | US | disclosed |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | ATLANTA PHARMA AG (DE) | 2004-07-08 | — | — | US | disclosed |
| EP-1385838-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | PDE4A, PDE4B, PDE3A | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.